Development and Optimization of Transdermal Patches of Losartan Potassium

The transdermal drug delivery system (TDDS) was developed to prolong drug release, increase medication bioavailability, and enhance patient adherence. Matrix dispersion type transdermal patches spread the drug in the solvent with the polymers and then allow the solvent to evaporate, resulting in a homogenous drug-polymer matrix. The purpose of this research was to develop a Losartan Potassium (LP) Transdermal patch and test its in-vitro sustain release using a 32 Factorial design. Using the solvent evaporation approach, an effort was made to produce a matrix-type transdermal treatment system including LP with various ratios of hydrophilic (HPMC E50) and hydrophobic (Ethyl cellulose) polymeric combinations. FTIR and DSC were used to investigate the drug's physicochemical compatibility with the polymers. The results revealed that the medication and the polymers were physically and chemically compatible. The patches were then put through a series of physical evaluations and a kinetic study. The F5 batch was deemed to be the best batch among all the formulations based on the findings of the physical assessment and kinetic investigations.